Corticosteroids for Guillain-Barré syndrome

Area of Science:

• Neurology
• Clinical Trials
• Immunology

Background:

• Guillain-Barré syndrome (GBS) involves peripheral nerve inflammation, suggesting potential benefit from corticosteroids.
• The study investigates corticosteroids for GBS recovery and long-term morbidity.

Purpose of the Study:

• To evaluate the efficacy of corticosteroids in accelerating recovery from Guillain-Barré syndrome.
• To assess the impact of corticosteroids on reducing long-term disability in GBS patients.

Main Methods:

• Systematic review of quasi-randomised or randomised controlled trials of corticosteroids in GBS.
• Inclusion of trials involving patients of all ages and GBS severity.
• Primary outcome: change in disability grade at four weeks; secondary outcomes: recovery time, mortality, and adverse events.

Main Results:

• No significant difference in disability grade between corticosteroid and non-corticosteroid groups overall.
• Oral corticosteroids were associated with significantly less improvement in disability at four weeks.
• Intravenous corticosteroids showed a non-significant trend towards improvement; no significant differences in secondary outcomes were observed.

Conclusions:

• Limited evidence suggests oral corticosteroids may significantly slow GBS recovery.
• Intravenous methylprednisolone alone offers no significant benefit or harm in GBS.
• Combination therapy with IVIg and methylprednisolone may hasten recovery but doesn't alter long-term outcomes; further research is needed.